Oxysterol-based Antimicrobial Platform Expansion
Other drug-resistant bacterial infections
Discovery/PreclinicalActive
Key Facts
Indication
Other drug-resistant bacterial infections
Phase
Discovery/Preclinical
Status
Active
Company
About Metaba
Metaba is an early-stage biotech targeting the global antimicrobial resistance (AMR) crisis with a novel oxysterol-based antibiotic platform. Originating from tuberculosis research, the company has expanded its scope to target other drug-resistant bacteria through hypothesis-driven metabolomic strategies. It is in the preclinical stage, building a leadership team with strong scientific and financial expertise, and actively engaging in partnerships and funding competitions to advance its pipeline.
View full company profile